A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

Inclusion Criteria:

- You must sign an informed consent document for clinical research.

- You must have Stage IIIB or Stage IV nonsquamous non-small cell lung cancer.

- You must not have received any prior treatment for your disease.

- Prior radiation therapy is allowed to < 25% of the bone marrow; however, prior
radiation to the whole pelvis is not allowed. If you have had radiation therapy to
the chest, you are not eligible to participate.

- You must be at least 18 years of age or older.

- You must have measureable tumor lesions according to the Response Evaluation Criteria
in Solid Tumors (RECIST) or disease can be evaluated on computed tomography (CT)
scan.

- Your test results assessing the function of blood forming tissue, kidneys and liver
must be satisfactory.

- Women must be sterile, postmenopausal or on contraception and men must be sterile
(for example post-vasectomy) or on contraception.

Exclusion Criteria:

- You cannot have clinically significant third-space fluid collections (e.g. ascites or
pleural effusions that cannot be controlled by drainage or other procedures).

- You cannot have Non-small Cell Lung Carcinoma (NSCLC) of predominantly squamous cell
histology.

- You cannot have known central nervous system (CNS) disease, other than stable,
treated brain metastasis.

- You cannot have undergone a surgical procedure, open biopsy, open pleurodesis, or
significant traumatic injury within 28 days of starting the study treatment, or have
an anticipated need for major surgery during the study.

- You cannot have a history of gastrointestinal fistula, perforation, or abscess,
inflammatory bowel disease, or diverticulitis.

- You are currently receiving ongoing treatment with full-dose warfarin or equivalent.

- You cannot have significant vascular disease, serious cardiac conditions (such as
heart attack), stroke or transient ischemic attack within 6 months of the trial.

- You cannot have evidence of bleeding diathesis or coagulopathy (in the absence of
therapeutic anticoagulation).

- You cannot have inadequately controlled hypertension, or a history of hypertensive
crisis or hypertensive encephalopathy.

- You cannot have a serious, nonhealing wound, active ulcer, or untreated bone
fracture.

- You cannot have another form of cancer, other than superficial basal cell and
superficial squamous (skin) cell, or carcinoma in situ of the cervix within the last
5 years.

- You cannot have received an investigational treatment within 30 days prior to the
trial.

- You cannot have previously received treatment with paclitaxel, carboplatin,
pemetrexed, or bevacizumab.

- You cannot be pregnant or breast-feeding.

- You cannot have a known sensitivity to any component of paclitaxel, carboplatin,
pemetrexed, or bevacizumab.

- You cannot have a history of hemoptysis (coughing blood) within 3 months prior to the
trial.

- You are unable to stop taking aspirin more than 1.3 grams per day or other
nonsteroidal anti-inflammatory drugs (NSAIDs).

- You are unable or unwilling to take folic acid or vitamin B12 supplementation.

- You are unable to take corticosteroids.

- You have any other on-going illnesses including active infections that may not allow
you to adhere to the requirements of the trial.